SNY241220P70000
- 0.00
- 0.000.00%
Sanofi Newsroom
Sanofi's Tolebrutinib Receives FDA Breakthrough Therapy Designation for NrSPMS
This week's US stock market hot stocks | The US version of HAIDILAO exceeds expectations! Darden Restaurants' stock price skyrocketed nearly 15%; Boeing, a component of the Dow, rose 4.36% against the trend this week, receiving a large order for 737 MAX a
This week, the Dow Jones Industrial Average has fallen by 3.39%, closing at 42,342.24 points; during the same period, the S&P 500 Index has decreased by 3.04%, closing at 5,867.08 points; the Nasdaq has dropped by 2.78%, closing at 19,372.77 points.
Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China
Express News | The Municipal Management Bureau has reached a preliminary consensus with Sanofi on the introduction of an innovative product for type 1 diabetes.
Express News | Sanofi and Jixing have reached an agreement on Aficamten in the Greater China market.
Express News | Cytokinetics Inc - Eligible for up to $150 Million in Milestone Payments From Sanofi
Express News | Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Sanofi: Kress Was the CEO of MorphoSys From 2019 Until It Was Acquired by Novartis in 2024
Sanofi: Appointment Is Subject to Ratification at Ordinary Shareholders' Meeting
Sanofi: This Is Effective From Jan. 1
Sanofi: Jean-Paul Kress Will Join Board of Directors
Presse Release: Jean-Paul Kress to Join Sanofi's Board of Directors
CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
European Equities Traded in the US as American Depositary Rise in Wednesday Trading
CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana
Sanofi (SNY.US) successfully introduced the TL1A monoclonal antibody for the treatment of inflammatory bowel disease in a Phase IIb study with an investment of 1.5 billion dollars.
In October 2023, Sanofi (SNY.US) reached an agreement with Teva for the development and commercialization of the drug, with an upfront payment of 0.5 billion dollars and milestone payments of up to 1 billion dollars.
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn Into More Strength?
Sanofi and Teva's Duvakitug Meets Primary Endpoints in Phase IIb Trial